Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy
Pluvinage, J. V.; Acero-Garces, D.; Greco, G.; Moseley, C. E.; Sidhu, S.; Zorn, K. C.; Kondapavulur, S.; Richie, M.; Douglas, V.; Mohan, S.; Neely, J.; Masciocchi, S.; Businaro, P.; Sarreon, A. G.; Gifreu, A.; McCutcheon, K.; Caspar, C.; Zamecnik, C.; Tubati, A.; Asencor, A. I.; Tugizova, M.; Louine, M.; Zuroff, L.; Gerdts, J.; Karalius, M.; Nylander, A.; Liu, M.; Daghlas, I.; Suleiman, L.; Nguyen, T.; Meyer, B.; Ibarra, K.; Chow, F.; Galati, A.; Mina, Y.; Toro, C.; Kang, M.; Shah, M.; Guterman, E. L.; Suen, C. G.; Guo, C.-Y.; Bevan, C.; Wesley, S. F.; Kvam, K.; Lee, S.; Abdelhak, A.; Martin,
Show abstract
BackgroundDisorders affecting the spinal cord (myelopathies) can cause severe disability. Despite diagnostic advances, approximately 12-18% of myelopathy cases continue to elude an etiological diagnosis, hampering effective treatment. MethodsThis retrospective, multicenter, tertiary care cohort study conducted from 2014 to 2025 evaluated archived biofluids from patients with IM, known autoimmune myelitis, or other neurological diseases (ONDs). Proteome-wide phage display was used to discover novel autoantibodies. Targeted immunoassays were used to screen for a candidate autoantibody. Downstream metabolites were measured in the cerebrospinal fluid (CSF). ResultsAutoantibodies targeting the transcobalamin receptor (CD320) responsible for cellular transport of vitamin B12 were identified in 18 out of 32 IM patients (56%) in a discovery cohort. Bioactive B12 concentration was decreased in the CSF of anti-CD320 positive patients compared to OND controls (P = 0.0273), indicative of autoimmune B12 central deficiency (ABCD). Compared to anti-CD320 negative IM cases, anti-CD320 positive IM cases demonstrated a higher frequency of subacute time course (56% vs 7%, P = 0.008), normal CSF profile (83% vs 50%, P = 0.044), and dorsolateral spinal cord abnormalities on magnetic resonance imaging (MRI) (61% vs 7%, P = 0.003). In two independent validation cohorts comprising 94 and 25 patients with IM, anti-CD320 was detected in 43 (46%) and 12 (48%) patients, respectively. Comorbid anti-CD320 was detected in a smaller proportion of patients with other known autoimmune etiologies of myelopathy. Five anti-CD320 positive IM patients received B12 supplementation with or without concurrent immunosuppression, and four out of five clinically improved. ConclusionsABCD is associated with a substantial proportion of IM. Screening for anti-CD320 followed by metabolic confirmation of a CNS-restricted B12 deficiency may be considered in the diagnostic evaluation of myelopathy.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic observational study 95%
- A novel mouse model of cerebral adrenoleukodystrophy highlights NLRP3 activity in lesion pathogenesis 94%
- Long term follow-up in anti-contactin-1 autoimmune nodopathy 94%
Similar papers in this journal
- CSF of SARS-CoV-2 patients with neurological syndromes reveals hints to understand pathophysiology 94%
- Persons with multiple sclerosis reveal distinct kynurenine pathway metabolite patterns: a multinational cross-sectional study 94%
- Distribution and Temporal Changes of Autoantibody-Mediated Pathogenic Mechanisms Among Acetylcholine Receptor-Positive Myasthenia Gravis Patients 94%
Similar papers in this journal
Similar papers in this journal
- SARS-CoV-2 mRNA vaccination fails to elicit humoral and cellular immune responses in multiple sclerosis patients receiving fingolimod 95%
- IgG1 pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality 95%
- Neuroinflammation predicts disease progression in progressive supranuclear palsy 92%
Similar papers in this journal
- Hybrid and vaccine-induced immunity against SARS-CoV-2 in MS patients on different disease-modifying therapies 94%
- Post-COVID sequelae in people with multiple sclerosis and related disorders: a multicenter cross-sectional study 94%
- Serum proteomic profiles of UK Biobank participants with Multiple Sclerosis 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.